胃食道逆流症(GERD)治療薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global GERD Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Product profiles

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Types of GERD
• Signs and symptoms
• Risk factors
• Diagnosis
• Treatment
• Usage of OTC drugs in GERD
• Epidemiology
• Economic burden

PART 06: Pipeline portfolio
• Information on pipeline candidates

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by drug class

PART 09: Global antacids market
• Introduction
• Market overview

PART 10: Global PPI drugs market
• Introduction
• Market overview

PART 11: Global H2 receptor antagonist drugs market
• Introduction
• Market overview

PART 12: Market segmentation by route of administration
• Oral
• Parenteral

PART 13: Market segmentation by dosage form
• Solid
• Liquid

PART 14: Geographical segmentation
• Global GERD drugs market segmentation by geography
• GERD drugs market in the Americas
• GERD drugs market in EMEA
• GERD drugs market in APAC

PART 15: Market drivers
• Lifestyle factors
• Overuse of medicines and dietary supplements
• Unmet medical needs
• Increase in prevalence of GERD
• Cost-effective OTC drugs

PART 16: Impact of drivers

PART 17: Market challenges
• Increased preference for CAM
• Adverse effects of drugs
• Generic erosion
• Counterfeit drugs

PART 18: Impact of drivers and challenges

PART 19: Market trends
• Self-medication
• Increase in awareness about GERD
• Intense competition
• Strategic alliances

PART 20: Vendor landscape
• Competitive scenario

PART 21: Key vendor analysis
• AstraZeneca
• Eisai
• GSK
• Johnson & Johnson
• Takeda
• Other prominent vendors

PART 22: Appendix
• List of abbreviations

PART 23: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Symptoms of pediatric GERD
Exhibit 03: GERD symptoms of older children and adolescents
Exhibit 04: Common risk factors for GERD
Exhibit 05: Dose, frequency, and average generic prices
Exhibit 06: Alternative treatment for GERD
Exhibit 07: Time line of the US FDA approved drugs for the treatment of GERD
Exhibit 08: Comparison between prescription and OTC drugs
Exhibit 09: Advantages and disadvantages of OTC drugs
Exhibit 10: Pipeline molecules for GERD
Exhibit 11: GERD clinical trials by development phase
Exhibit 12: GERD clinical trials by trial status
Exhibit 13: Global GERD drugs market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Global GERD drugs market segmentation by drug class
Exhibit 16: Global GERD drugs market segmentation by drug class 2015
Exhibit 17: Global antacids market 2015-2020 ($ billions)
Exhibit 18: PPI sales in major non-US markets 2013 ($ millions)
Exhibit 19: Global PPIs market 2015-2020 ($ billions)
Exhibit 20: Global H2 receptor antagonists market 2015-2020 ($ billions)
Exhibit 21: Global GERD drugs market segmentation by route of administration
Exhibit 22: Global GERD drugs market segmentation by dosage form
Exhibit 23: Global GERD drugs market by geography 2015
Exhibit 24: Global GERD drugs market by geography 2015-2020 ($ billions)
Exhibit 25: GERD drugs market in the Americas 2015-2020 ($ billions)
Exhibit 26: GERD drugs market in EMEA 2015-2020 ($ billions)
Exhibit 27: GERD drugs market in APAC 2015-2020 ($ billions)
Exhibit 28: Impact of drivers
Exhibit 29: Common side effects associated with Nexium, Prontonix, Aciphex, and other heartburn medications
Exhibit 30: Impact of drivers and challenges
Exhibit 31: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 32: AstraZeneca: Business segmentation by revenue 2014
Exhibit 33: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 34: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 35: AstraZeneca: YoY revenue growth of Nexium 2012-2014 ($ billions)
Exhibit 36: AstraZeneca: YoY revenue growth of Losec 2012-2014 ($ millions)
Exhibit 37: AstraZeneca: YoY revenue growth of Vimovo 2012-2014 ($ millions)
Exhibit 38: AstraZeneca: Key takeaways
Exhibit 39: Eisai: Business segmentation by revenue 2014
Exhibit 40: Eisai: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 41: Eisai: YoY revenue growth of Pariet 2011-2014 ($ billions)
Exhibit 42: Eisai: Key takeaways
Exhibit 43: GSK: Business segmentation by revenue 2014
Exhibit 44: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 45: GSK: Geographical segmentation by revenue 2014
Exhibit 46: GSK: Key takeaways
Exhibit 47: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 48: Johnson & Johnson: Business segmentation 2013 and 2014 by revenue ($ billions)
Exhibit 49: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 50: Johnson & Johnson: Key takeaways
Exhibit 51: Takeda: Business segmentation by revenue 2014
Exhibit 52: Takeda: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 53: Takeda: Geographical segmentation by revenue 2014
Exhibit 54: Takeda: YoY revenue growth of Prevacid 2012-2014 ($ billions)
Exhibit 55: Takeda: YoY revenue growth of Dexilant 2012-2014 ($ billions)
Exhibit 56: Takeda: YoY revenue growth of Protonix 2012-2014 ($ billions)
Exhibit 57: Takeda: Key takeaways


【レポート販売概要】

■ タイトル:胃食道逆流症(GERD)治療薬の世界市場2016-2020
■ 英文:Global GERD Market 2016-2020
■ 発行日:2016年1月20日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8134
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。